Moderna rises after co's influenza vaccine superior to licensed shot in study

Shares of vaccine maker Moderna MRNA.O rise 3% to $27.98 premarket

Moderna says its experimental influenza vaccine, mRNA-1010, showed superior efficacy compared with a licensed standard-dose seasonal flu shots in adults aged 50 years and older in a late-stage study

The experimental vaccine, mRNA-1010, was 27.4% more effective in preventing influenza illness in participants aged 65 ages and older compared with a standard-dose seasonal influenza vaccine, co says

The late-stage trial enrolled 40,805 adults aged 50 years and older across 11 countries

Company says it plans to engage with regulators on filing submissions for the vaccine candidate

As of last close, stock down 34.7% YTD